{"symbol":"REGN","fiscalQuarter":"Q1-2021","reportDate":"2021-05-06","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2021","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Up 3.37%","keyNumbers":[{"metric":"EPS","actual":"$9.89","expected":"N/A","surprise":"+27.12%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on advancing our pipeline and ensuring patient access to our therapies."],"summary":"Management expressed satisfaction with the strong EPS results, highlighting their commitment to innovation. They emphasized the importance of maintaining access to their products for patients."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron's strong EPS performance, exceeding expectations by over 27%, has positively impacted investor sentiment, resulting in a 3.37% increase in stock price. The company did not provide revenue figures or guidance, leaving some uncertainty for investors. However, the focus on advancing their product pipeline suggests potential for future growth.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2021 earnings: EPS beat by 27.12%. Stock up 3.37%. Full breakdown."}}